Acute Promyelocytic Leukemia: A Long-Term Retrospective Study in Mexico

Zapata-Canto, Nidia; Aguilar, Manuel; Arana, Luara; Montano, Efren; Ramos-Peñafiel, C.O.; Pena, Jose Antonio De la; Álvarez-Vera, José L.; Espitia-Rios, Eugenia; Pérez-Zúñiga, Juan Manuel; Hernández-Ruiz, Eleazar; Cervera, Eduardo; Espinoza-Zamora, Ramiro; Sosa-Espinoza, Alejandro; Solís-Poblano, Juan Carlos; Demichelis‐Gómez, Roberta; Gómez‐Almaguer, David; Barrera, Esperanza; Mijangos, Javier; Solis-Armenta, Ruben; Perez, Oscar; Herrera, Miguel Angel Rubio; Díaz-Vargas, Guillermo; Cabrera-García, Álvaro; Flores-Jiménez, Juan Antonio; Morales-Adrián, Javier de Jesús; Ramirez-Romero, Eva Fabiola; Ceballos-López, Adrián Alejandro; Guillermo, Victor Antonio; Manuel, Manuel Solano; Lourdes, Esthela Juan Lien-Chang; Ojeda-Tovar, Juan; Gomez-Perdomo, Gladys; Alvarado-Ibarra, Martha

doi:10.14740/jh773

J Hematol

2021

DOI: 10.14740/jh773

|View full text |Cite

Acute Promyelocytic Leukemia: A Long-Term Retrospective Study in Mexico

Nidia Zapata-Canto¹,

Manuel Aguilar²,

Luara Arana³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This rate aligns with international trials but is lower than similar retrospective studies in the same timeframe reporting early mortality rates above 10%. 12,13 This outcome is likely due to a smaller cohort of high-risk patients, prompt diagnosis enhanced supportive therapy protocols, and the presence of a specialized Hematological Emergency Department at our institution.…”

mentioning

confidence: 99%

Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort

Costa,

Carmosino,

Scalzulli

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort

Costa,

Carmosino,

Scalzulli

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

show abstract

Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time

Scalzulli,

Costa,

Carmosino

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

A comprehensive analysis of 220 patients diagnosed with APL between 1993 and 2022 is here reported. Overall, 214 patients (97.2%) received induction therapy. Complete response (CR) was achieved in 97.4%, 100%, 100%, and 27% of patients treated with AIDA protocol, AIDA + Ara-C, ATRA + ATO, and ATRA monotherapy, respectively. Molecular complete response (CRMRD-) was achieved in 96.8% cases, and 142 patients proceeded to maintenance therapy. Overall, the 3-year and 5-year overall survival (OS) rates were 80.8% (95% CI, 78.1–83.5) and 79.1% (95% CI, 76.4–81.8), respectively. Considering only patients who completed induction and maintenance therapy, the 5-year OS rates were 82.1% (95% CI, 77.5–86.7) for the AIDA0493 cohort, 87.5% (95% CI, 84.4–91.1) for the AIDA2000 cohort, and 100% for the APL0406 cohort (p = 0.044). Additionally, the disease-free survival (DFS) rates were 65.7% (95% CI, 60.4–70.9), 70% (95% CI, 65.8–75.2), and 95.1% (95% CI, 91.7–98.5) (p = 0.016), respectively. Among low and intermediate-risk patients, age > 70 years (p = 0.027) and relapse (p < 0.001) were significantly associated with reduced outcomes. This study contributes to the advancement of our understanding of APL treatment, underscoring the ongoing need for research to enhance outcomes and explore new therapeutic approaches and prognostic factors.

show abstract

Acute myeloid leukemia: challenges for diagnosis and treatment in Latin America

et al. 2023

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Acute Promyelocytic Leukemia: A Long-Term Retrospective Study in Mexico

Cited by 3 publications

References 45 publications

Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort

Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort

Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time

Acute myeloid leukemia: challenges for diagnosis and treatment in Latin America

Contact Info

Product

Resources

About